- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Congenital nystagmus.
Displaying page 1 of 1.
EudraCT Number: 2007-007663-25 | Sponsor Protocol Number: MRZ 92579-0738/1 | Start Date*: 2008-11-17 | ||||||||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | ||||||||||||||||||
Full Title: A Long-Term Open Label Extension Study to assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus. | ||||||||||||||||||
Medical condition: congenital idiopathic nystagmus and aquired nystagmus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002595-34 | Sponsor Protocol Number: MRZ 92579-0707/1 | Start Date*: 2008-03-11 | ||||||||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | ||||||||||||||||||
Full Title: Efficacy and safety of neramexane mesylate in congenital idiopathic nystagmus and acquired nystagmus: a randomized, double-blind, placebo-controlled, single center, proof of concept study using a t... | ||||||||||||||||||
Medical condition: Congenital idiopathic nystagmus and acquired nystagmus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004297-40 | Sponsor Protocol Number: Version 3 February 2010 | Start Date*: 2008-04-25 |
Sponsor Name:University Hospitals of Leicester NHS Trust | ||
Full Title: Pharmacological treatment of nystagmus: A randomised double masked placebo controlled crossover study using gabapentin and memantine. | ||
Medical condition: Nystagmus | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004058-11 | Sponsor Protocol Number: RM-493-023 | Start Date*: Information not available in EudraCT |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström syndrome (AS) Patients with Moderate to Severe Obesity | ||
Medical condition: Obesity and hyperphagia in patients with Bardet-Biedl Syndrome or Alström syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
